These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18302515)

  • 1. High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.
    Mikosch P; Kerschan-Schindl K; Woloszczuk W; Stettner H; Kudlacek S; Kresnik E; Gallowitsch HJ; Lind P; Pietschmann P
    Thyroid; 2008 Jan; 18(1):27-33. PubMed ID: 18302515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
    Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
    Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
    Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism.
    Mikosch P; Jauk B; Gallowitsch HJ; Pipam W; Kresnik E; Lind P
    Thyroid; 2001 Mar; 11(3):257-63. PubMed ID: 11327617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels.
    Martini G; Gennari L; De Paola V; Pilli T; Salvadori S; Merlotti D; Valleggi F; Campagna S; Franci B; Avanzati A; Nuti R; Pacini F
    Thyroid; 2008 Apr; 18(4):455-60. PubMed ID: 18399769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
    Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
    Łacka K
    Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of cathepsin K decrease with age in both women and men.
    Kerschan-Schindl K; Hawa G; Kudlacek S; Woloszczuk W; Pietschmann P
    Exp Gerontol; 2005 Jun; 40(6):532-5. PubMed ID: 15935595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
    Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
    Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
    Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.
    Skoumal M; Haberhauer G; Kolarz G; Hawa G; Woloszczuk W; Klingler A
    Arthritis Res Ther; 2005; 7(1):R65-70. PubMed ID: 15642144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine.
    Zulewski H; Siggelkow H; Walden C; Becker W; Hüfner M
    Exp Clin Endocrinol Diabetes; 1999; 107(3):190-4. PubMed ID: 10376444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
    Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
    Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
    Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
    Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.